Johnson and Johnson (JNJ) 뉴스

Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology

Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with...

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Johnson & Johnson Reports Q4 and Full-Year 2024 Results

2024 Fourth-Quarter reported sales growth of 5.3% to $22.5 Billion with operational growth of 6.7%* and adjusted operational growth of 5.7...

SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression

SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with...

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing...

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and...

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and...

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis

Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis PR...

Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease

Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for...

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically...

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025

Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2025 of $1.24...

Form 4 - Statement of changes in beneficial ownership of securities